Ebola virus disease: Basics the medical specialist should know

Netherlands Journal of Critical Care

Volumn 22, Issue 4, 2015, Pages 6-14

  Grobusch, M P ^a   Visser, B J ^a   Boersma, J ^a   Huson, M A ^a   Janssen, S ^a   Greve, P ^a   Browne, J L ^b   Van Der Ende Bouwman, C ^c   Van Der Ende, J ^c   Zwinkels, N ^c   Huizenga, E ^c   De Bree, G J ^a,d   Stijnis, C ^a   Van Vugt, M ^a   Goorhuis, A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c Lion Heart Medical Center   (Sierra Leone)

^d AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT   (Netherlands)

Author keywords

Bundibugyo virus; Critical care; Ebola; Ebola haemorrhagic fever; Ebola virus; Ebola virus disease; Ebolavirus; Epidemic; Guinea; Liberia; Outbreak; Reston virus; Sierra Leone; Sudan virus; Ta forest virus; Zaire ebola virus

Indexed keywords

AVI 7537; FAVIPIRAVIR; IMMUCILLIN A; TKM 100802; ZMAPP;

ACUTE KIDNEY FAILURE; ANTIMICROBIAL THERAPY; CLINICAL FEATURE; CONTINUOUS RENAL REPLACEMENT THERAPY; CONVALESCENCE; DIFFERENTIAL DIAGNOSIS; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; EXCHANGE BLOOD TRANSFUSION; HUMAN; INCUBATION TIME; INFECTION PREVENTION; LABORATORY DIAGNOSIS; NONHUMAN; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA TRANSFUSION; REHYDRATION; RESPIRATORY TRACT INTUBATION; REVIEW; VIRUS CARRIER; VIRUS TRANSMISSION;

EID: 84942115910     PISSN: 15693511     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. WHO Ebola response team. Ebola virus disease in West Africa - The first 9 months of the epidemic and forward projections. N Engl J Med. 2014;371:1481-95.
2. World Health Organization. Statement on the 1st meeting of the IHR emergency committee on the 2014 Ebola outbreak in West Africa. 8 August 2014. [Internet].
3. World Health Organization. Global alert and response (GAR). Ebola situation report. 11 February 2015.
4. Goeijenbier M, van Kampen JJA, Reusken CBEM, Koopmans MPG, van Gorp ECM. Ebola virus disease: a review on epidemiology, symptoms, treatment and pathogenesis. Neth J Med. 2014;72:442-8.
5. Centers of Disease Control and Prevention (CDC). Outbreaks Chronology: Ebola virus disease [Internet]. [cited 17 Feb 2015]. Available: http://www.cdc.gov/vhf/ebola/outbreaks/history/chronology.html
6. Saez AM, Weiss S, Nowak K, et al. Investigating the zoonotic origin of the West African Ebola epidemic. EMBO Mol Med. 2014;7:17-23.
7. Leroy EM, Labouba I, Maganga GD, Berthet N. Ebola in West Africa: the outbreak able to change many things. Clin Microbiol Infect. 2014;20:O597-9.
8. Peterson AT, Carroll DS, Mills JN, Johnson KM. Potential mammalian filovirus reservoirs. Emerg Infect Dis. 2004;10:2073-81.
9. Leroy EM, Kumulungui B, Pourrut X, et al. Fruit bats as reservoirs of Ebola virus. Nature. 2005;438:575-6.
10. Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet. 2011;377:849-62.
11. Alimonti J, Leung A, Jones S, et al. Evaluation of transmission risks associated with in vivo replication of several high containment pathogens in a biosafety level 4 laboratory. Sci Rep. 2014;4:5824.
12. Weingartl HM, Embury-Hyatt C, Nfon C, Leung A, Smith G, Kobinger G. Transmission of Ebola virus from pigs to non-human primates. Sci Rep. 2012;2:811.
13. Johnson E, Jaax N, White J, Jahrling P. Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus. Int J Exp Pathol. 1995;76:227-36.
14. Sanchez A, Lukwiya M, Bausch D, et al. Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels. J Virol. 2004;78:10370-7.
15. Hensley LE, Geisbert TW. The contribution of the endothelium to the development of coagulation disorders that characterize Ebola hemorrhagic fever in primates. Thromb Haemost. 2005;94:254-61.
16. Escudero-Pérez B, Volchkova VA, Dolnik O, Lawrence P, Volchkov VE. Shed GP of Ebola virus triggers immune activation and increased vascular permeability. PLoS Pathog. 2014;10:e1004509.
17. Hensley LE, Stevens EL, Yan SB, et al. Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J Infect Dis. 2007;196(Suppl):S390-9.
18. Misasi J, Sullivan NJ. Camouflage and Misdirection: The Full-On Assault of Ebola Virus Disease. Cell. 2014;159:477-86.
19. Mohan GS, Li W, Ye L, Compans RW, Yang C. Antigenic subversion: a novel mechanism of host immune evasion by Ebola virus. PLoS Pathog. 2012;8:e1003065.
20. Roels TH, Bloom AS, Buffington J, et al. Ebola hemorrhagic fever, Kikwit, Democratic Republic of the Congo, 1995: risk factors for patients without a reported exposure. J Infect Dis. 1999;179(Suppl):S92-7.
21. Schieffelin JS, Shaffer JG, Goba A, et al. Clinical illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med. 2014;371:2092-100.
22. Eichner M, Dowell SF, Firese N. Incubation period of ebola hemorrhagic virus subtype zaire. Osong Public Heal Res Perspect. 2011;2:3-7.
23. Chertow DS, Kleine C, Edwards JK, Scaini R, Giuliani R, Sprecher A. Ebola virus disease in West Africa--clinical manifestations and management. N Engl J Med. 2014;371:2054-7.
24. Maganga GD, Kapetshi J, Berthet N, et al. Ebola Virus Disease in the Democratic Republic of Congo. N Engl J Med. 2014;371:2083-91.
25. Bah EI, Lamah M-C, Fletcher T, et al. Clinical presentation of patients with Ebola virus disease in Conakry, Guinea. N Engl J Med. 2015;372:40-7.
26. Agua-Agum J, Ariyarajah A, Blake IM, et al. Ebola virus disease among children in West Africa. N Engl J Med. 2015;372:1274-7.
27. Baggi FM, Taybi A, Kurth A, et al. Management of pregnant women infected with Ebola virus in a treatment centre in Guinea, June 2014. Euro Surveill. 2014;11:19(49).
28. Jamieson DJ, Uyeki TM, Callaghan WM, Meaney-Delman D, Rasmussen SA. What obstetrician-gynecologists should know about Ebola: a perspective from the Centers for Disease Control and Prevention. Obstet Gynecol. 2014;124:1005-10.
29. Kreuels B, Wichmann D, Emmerich P, et al. A case of eevere Ebola virus infection complicated by Gram-negative septicemia. N Engl J Med. 2014;371:2394-401.
30. Lyon GM, Mehta AK, Varkey JB, et al. Clinical care of two patients with Ebola virus disease in the United States. N Engl J Med. 2014;371:2402-9.
31. Wolf T, Kann G, Becker S, et al. Severe Ebola virus disease with vascular leakage and multiorgan failure: treatment of a patient in intensive care. Lancet. 2015;385:1428-35.
32. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Kagan E, Hensley LE. Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis. 2003;188:1618-29.
33. McElroy AK, Erickson BR, Flietstra TD, et al. Ebola hemorrhagic Fever: novel biomarker correlates of clinical outcome. J Infect Dis. 2014;210:558-66.
34. World Health Organization. Ebola virus disease. Fact Sheet n°103 [Internet]. [cited 17 Feb 2015]. Available: http://www.who.int/mediacentre/factsheets/fs103/en/
35. Varkey JB, Shantha JG, Crozier I, et al. Persistence of Ebola virus in ocular fluid during convalescence. N Engl J Med. 2015;372:2423-7.
36. Centers for Disease Control and Prevention (CDC). Considerations for discharging people under investigation for Ebola virus disease [Internet]. [cited 30 Mar 2015]. Available: http://www.cdc.gov/vhf/ebola/healthcare-us/ evaluating-patients/discharging.html
37. World Health Organization. Laboratory guidance for the diagnosis of Ebola virus disease, interim recommendations [Internet]. [cited 30 Mar 2015]. Available: http://apps.who.int/iris/bitstream/10665/134009/1/WHO_EVD_GUIDANCE_LAB_14.1_eng.pdf
38. Petersen E, Maiga B. Guidelines for treatment of patients with Ebola virus diseases are urgently needed. Int J Infect Dis. 2015;30:85-6.
39. Boggild AK, Esposito DH, Kozarsky PE, et al. Differential diagnosis of illness in travelers arriving from Sierra Leone, Liberia, or Guinea: a cross-sectional study from the GeoSentinel Surveillance Network. Ann Intern Med. 2015;162:757-64.
40. Connor MJ, Kraft C, Mehta AK, et al. Successful delivery of RRT in Ebola virus disease. J Am Soc Nephrol. 2015;26:31-7.
41. Kidney Disease Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl. 1. 2012
42. Centers for Disease Control and Prevention (CDC). Recommendations for safely performing acute hemodialysis in patients with Ebola virus disease in U.S. hospitals [Internet]. [cited 5 Apr 2015]. Available: https://c--nulacfcckiw.sec.amc.nl/vhf/ebola/hcp/guidance-dialysis.html
43. Crosswell A, Brain MJ, Roodenburg O. Vascular access site influences circuit life in continuous renal replacement therapy. Crit Care Resusc. 2014;16:127-30.
44. Gervasio JM, Garmon WP, Holowatyj M. Nutrition support in acute kidney injury. Nutr Clin Pract. 2011;26: 374-81.
45. Wiesen P, Van Overmeire L, Delanaye P, Dubois B, Preiser J-C. Nutrition disorders during acute renal failure and renal replacement therapy. JPEN J Parenter Enteral Nutr. 2011;35:217-22.
46. World Health Organization. Therapies [Internet]. [cited 18 Mar 2015]. Available: http://www.who.int/medicines/ebola-treatment/emp_ebola_therapies/en/
47. World Health Organization. Ebola vaccines, therapies, and diagnostics - Questions and Answers [Internet]. 2015 [cited 18 Mar 2015]. Available: http://www.who.int/medicines/emp_ebola_q_as/en/
48. De Clercq E. Ebola virus (EBOV) infection: therapeutic strategies. Biochem Pharmacol. 2015;93:1-10.
49. World Health Organization. Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease Empirical treatment during outbreaks. Geneva; 2014.
50. Burnouf T, Seghatchian J. Ebola virus convalescent blood products: Where we are now and where we may need to go. Transfus Apher Sci. 2014;51:120-5.
51. Chippaux J-P, Boyer LV, Alagón A. Post-exposure treatment of Ebola virus using passive immunotherapy: proposal for a new strategy. J Venom Anim Toxins Incl Trop Dis. 2015;21:3.
52. World Health Organization. Position paper on collection and use of convalescent plasma or serum as an element in filovirus outbreak response. BRN. 2014
53. Oestereich L, Lüdtke A, Wurr S, Rieger T, Muñoz-Fontela C, Günther S. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res. 2014;105:17-21.
54. Smither SJ, Eastaugh LS, Steward JA, Nelson M, Lenk RP, Lever MS. Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model. Antiviral Res. 2014;104:153-5.
55. MSF. Clinical trial for potential Ebola treatment started in MSF clinic in Guinea [Internet]. [cited 18 Mar 2015]. Available: http://www.msf.org/article/clinical-trialpotential-ebola-treatment-started-msf-clinic-guinea
56. Qiu X, Wong G, Audet J, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature. 2014;514:47-53.
57. Mapp Biopharmaceutical [Internet]. [cited 21 Jan 2014]. Available: http://www.mappbio.com/
58. Mapp & Leaf Biopharmaceutical. LeafBio Announces Acceptance of Investigational New Drug Application for Ebola Therapy ZMappTM. 2015.
59. Geisbert TW, Lee ACH, Robbins M, et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-ofconcept study. Lancet. 2010;375:1896-905.
60. Tekmira. Tekmira Receives Notice of Clinical Hold for TKM-Ebola Phase I Clinical Trial [Internet]. [cited 21 Jan 2015]. Available: http://investor.tekmirapharm.com/releasedetail.cfm?ReleaseID=857714
61. University of Oxford. New Ebola treatment trial starts in Sierra Leone [Internet]. 2015 [cited 19 Mar 2015]. Available: http://www.ox.ac.uk/news/2015-03-11-newebola-treatment-trial-starts-sierra-leone
62. Warren TK, Wells J, Panchal RG, et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX 4430. Nature. 2014;508:402-5.
63. Iversen PL, Warren TK, Wells JB, et al. Discovery and early development of AVI- 7537 and AVI-7288 for the treatment of Ebola virus and Marburg virus infections. Viruses. 2012;4:2806-30.
64. Rampling T, Ewer K, Bowyer G, et al. A Monovalent chimpanzee adenovirus Ebola vaccine — preliminary report. N Engl J Med. 2015 Jan 28.
65. Agnandji ST, Huttner A, Zinser ME, et al. Phase 1 trials of rVSV Ebola caccine in Africa and Europe - preliminary report. N Engl J Med. 2015 Apr 1.
66. Regules JA, Beigel JH, Paolino KM, et al. A Recombinant vesicular stomatitis virus Ebola vaccine - preliminary report. N Engl J Med. 2015 Apr 1.
67. National Institute of Allergy and Infectious Diseases (NIAID). Ebola Vaccine Trial Opens in Liberia [Internet]. [cited 13 Apr 2015]. Available: http://www.niaid.nih.gov/news/newsreleases/2015/Pages/PREVAIL.aspx
68. Missair A, Marino MJ, Vu CN, et al. Anesthetic Implications of Ebola patient management: a review of the literature and policies. Anesth Analg. 2014 Dec 30.
69. Netherlands Institute for Public Health and the Environment (Rijksinstituut voor Volksgezondheid en Milieu). LCI-richtlijn Virale hemorragische koorts Filovirussen (ebola, marburg) [Internet]. [cited 13 Apr 2015]. Available: http://www.rivm.nl/Documenten_en_publicaties/Professioneel_Praktisch/Richtlijnen/Infectieziekten/LCI_richtlijnen/LCI_richtlijn_Virale_hemorragische_koorts_Filovirussen_ebola_marburg